- **Unichem Laboratories is a pharmaceutical company built to make high-quality generic medicines and then sell them around the world, with the United States as its anchor market. Founded in 1944 by the late Shri Amrut Mody, the company spent decades building an integrated operation in India before making two defining moves: it sold its domestic formulations business in India and Nepal in 2017 to focus exclusively on international markets, and then in 2023 it became a subsidiary of Ipca Laboratories, a larger global pharmaceutical company with a complementary product range and deep cost advantages. The recurring logic behind everything Unichem does is vertical integration - it makes its own active pharmaceutical ingredients (the molecules that give a medicine its effect) in its own factories, turns them into finished tablets and capsules in its own formulation plants, and then sells those finished products through its own subsidiaries in markets from the US to Brazil to South Africa, capturing margin at every step and controlling quality from raw material to pharmacy shelf.** # Business segments A single integrated engine - generic formulations for international markets, built on a foundation of captive API manufacturing and a shared R&D pipeline - where every part feeds the same export machine. ## 1. International generics formulations: the export engine **The company makes tablets, capsules, injectables and creams in three Indian factories and sells them in 65 countries, with the United States alone generating 65% of total revenue through a wholly owned American subsidiary.** - **America is the main customer** - the US business runs through Unichem Pharmaceuticals (USA) Inc., a material subsidiary that buys finished products from the parent company and distributes them to wholesalers, healthcare providers and government institutions, making it the single largest contributor to company revenue. - **Exports are almost everything** - on a consolidated basis, 98.5% of sales revenue came from outside India in the most recent year, with key markets beyond the US including Brazil, Europe and South Africa. - **Three plants, many formats** - the company operates formulation factories in Goa, Baddi (Himachal Pradesh) and Ghaziabad (Uttar Pradesh), together producing roughly 9.4 billion tablets and capsules in a single year, alongside liquid orals, creams, ointments and injectables. - **Regulatory approvals are the licence to sell** - every factory is accredited by a long list of global health regulators including the US FDA, the UK MHRA, Brazil's ANVISA, and Japan's PMDA, meaning the company can ship products into the world's most demanding markets without a separate partner's sign-off. - **Moving up the complexity ladder** - to escape the price erosion that hits simple generics, R&D is now aimed at modified-release pills, long-acting injectables and inhalation products, while a contract manufacturing arm produces medicines to order for other pharmaceutical companies. ## 2. Active pharmaceutical ingredients: the make-it-ourselves backbone **The company manufactures its own active pharmaceutical ingredients - the therapeutic molecules inside every pill - at three Indian sites, feeding its own formulation plants and reducing dependence on outside suppliers.** - **Captive supply is the point** - the API factories exist primarily to feed Unichem's own formulation plants, which gives the company control over quality, keeps supply chains short, and cuts out the margin a third-party API supplier would charge. - **Three factories, recently expanded** - API manufacturing takes place at Pithampur (Madhya Pradesh), Roha and Kolhapur (both in Maharashtra), with the Pithampur site recently completing a capacity expansion that added roughly 210 kilolitres of reactor volume, lifting installed capacity by 81%. - **Regulatory scrutiny is constant** - the API plants are inspected by the US FDA and other global regulators; the Pithampur and Kolhapur sites both underwent FDA inspections recently, receiving classifications that allow continued supply to the American market. - **China dependency is the vulnerability** - India imports roughly 70% of its API needs from China, and the Indian pharma industry depends heavily on imports for API and basic chemicals, which is why the industry is suggesting incentivising R&D to reduce dependency on imports. # Research and development: the pipeline factory **A 300-scientist Centre of Excellence in Goa generates the new products, patent-proof processes and regulatory filings that keep the export engine fed - it is the shared capability behind every segment.** - **One centre, every dosage form** - the Goa R&D facility houses teams for API process research, formulation development, clinical research and intellectual property management, with a separate facility for injectables and pre-formulation laboratories. - **Filing cabinet to the world** - the R&D output over the years includes 84 ANDA filings (the applications needed to sell generics in the US, of which 70 are approved), 79 US drug master files, 36 European CEPs, and filings for Japan and China, creating a catalogue of products that can be launched across multiple geographies. - **Biotech and green chemistry on the side** - a bio-tech facility develops biosimilar products using recombinant DNA technology, while enzyme-based chemical processes have cut raw material costs and replaced harsher traditional chemistry with greener alternatives. # Group structure and partners **Unichem is a listed Indian company controlled by Ipca Laboratories, which owns just over half the shares and provides raw-material buying power, while five wholly owned subsidiaries in the US, UK, Brazil, South Africa and China do the selling.** - **Ipca is the controlling shareholder** - since 2023, Ipca Laboratories has held 52.67% of Unichem's equity, and the two companies describe their portfolios as highly complementary: Unichem brings a track record in regulated markets and differentiated products, while Ipca brings cost-competitive API manufacturing and a presence in over 100 countries. - **Synergies are practical, not theoretical** - the parent relationship translates into centralised raw-material purchasing that lowers input costs and shared logistics that cut freight expenses, while the registered office was physically moved to Kandivali, Mumbai, to sit alongside Ipca's large existing set-up there. - **Subsidiaries are the local face** - the Company has six subsidiaries, including a wholly owned subsidiary in China incorporated in June 2019 to register products, expand finished formulations, and secure the API supply chain. - **An associate fills a clinical gap** - Unichem holds a 32.11% stake in Synchron Research Services, a contract research organisation in India that runs clinical trials for pharmaceutical companies, giving the group access to bioequivalence and clinical study capabilities without owning them outright. - **Non-core assets are being cleared** - the company sold its stake in an API manufacturer called Optimus Drugs in 2022, closed a loss-making Irish manufacturing facility owned by its UK subsidiary, transferred the Irish subsidiary itself to Ipca, and in 2025 agreed to sell its former Mumbai registered office land and buildings for Rs 279 crores.